Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target Raised to $779.00

Regeneron Pharmaceuticals (NASDAQ:REGN) had its price target upped by Morgan Stanley from $758.00 to $779.00 in a research note published on Wednesday,Benzinga reports. They currently have an equal weight rating on the biopharmaceutical company’s stock.

Several other analysts also recently issued reports on the company. Sanford C. Bernstein raised Regeneron Pharmaceuticals to a “hold” rating in a research report on Wednesday, July 29th. Piper Sandler reduced their price objective on Regeneron Pharmaceuticals from $855.00 to $854.00 and set an “overweight” rating on the stock in a research note on Thursday, July 9th. Wall Street Zen upgraded Regeneron Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Sunday, September 20th. HSBC boosted their price target on Regeneron Pharmaceuticals from $800.00 to $920.00 and gave the stock a “buy” rating in a research report on Thursday, September 10th. Finally, Wells Fargo & Company upped their price target on Regeneron Pharmaceuticals from $700.00 to $750.00 and gave the stock an “equal weight” rating in a report on Friday, July 31st. One equities research analyst has rated the stock with a Strong Buy rating, twenty-one have issued a Buy rating and nine have issued a Hold rating to the company. According to MarketBeat, Regeneron Pharmaceuticals currently has an average rating of “Moderate Buy” and an average price target of $834.24.

Regeneron Pharmaceuticals Price Performance

Regeneron Pharmaceuticals stock opened at $746.54 on Wednesday. Regeneron Pharmaceuticals has a 52-week low of $541.00 and a 52-week high of $859.34. The firm has a fifty day moving average of $790.99 and a 200-day moving average of $720.67. The firm has a market capitalization of $76.86 billion, a P/E ratio of 18.45, a PEG ratio of 1.39 and a beta of 0.16. The company has a quick ratio of 2.78, a current ratio of 3.34 and a debt-to-equity ratio of 0.06.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its earnings results on Thursday, July 30th. The biopharmaceutical company reported $14.29 EPS for the quarter, beating analysts’ consensus estimates of $10.16 by $4.13. The business had revenue of $4.29 billion for the quarter, compared to the consensus estimate of $3.82 billion. Regeneron Pharmaceuticals had a net margin of 27.86% and a return on equity of 13.47%. The business’s revenue for the quarter was up 16.7% compared to the same quarter last year. During the same quarter last year, the firm posted $12.81 EPS. As a group, analysts predict that Regeneron Pharmaceuticals will post 46.21 EPS for the current year.

Regeneron Pharmaceuticals Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Monday, August 31st. Stockholders of record on Tuesday, August 18th were given a $0.94 dividend. The ex-dividend date of this dividend was Tuesday, August 18th. This represents a $3.76 annualized dividend and a dividend yield of 0.5%. Regeneron Pharmaceuticals’s payout ratio is presently 9.29%.

Insider Transactions at Regeneron Pharmaceuticals

In other news, Director Huda Zoghbi sold 800 shares of the company’s stock in a transaction dated Monday, August 10th. The shares were sold at an average price of $800.00, for a total value of $640,000.00. Following the sale, the director owned 1,703 shares in the company, valued at approximately $1,362,400. This represents a 31.96% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Marion Mccourt sold 1,131 shares of the stock in a transaction dated Thursday, September 3rd. The stock was sold at an average price of $857.39, for a total transaction of $969,708.09. Following the transaction, the executive vice president directly owned 12,003 shares in the company, valued at $10,291,252.17. The trade was a 8.61% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders sold 3,946 shares of company stock valued at $3,302,458. Insiders own 6.97% of the company’s stock.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of REGN. BlackRock Inc. acquired a new position in shares of Regeneron Pharmaceuticals in the 2nd quarter worth approximately $5,682,636,000. State Street Corp raised its position in shares of Regeneron Pharmaceuticals by 3.6% during the 2nd quarter. State Street Corp now owns 4,834,688 shares of the biopharmaceutical company’s stock valued at $3,014,621,000 after acquiring an additional 170,210 shares in the last quarter. Nuveen LLC lifted its stake in Regeneron Pharmaceuticals by 71.1% during the fourth quarter. Nuveen LLC now owns 2,010,517 shares of the biopharmaceutical company’s stock worth $1,551,858,000 after purchasing an additional 835,240 shares during the last quarter. Invesco Ltd. lifted its stake in Regeneron Pharmaceuticals by 7.2% during the fourth quarter. Invesco Ltd. now owns 1,591,105 shares of the biopharmaceutical company’s stock worth $1,228,127,000 after purchasing an additional 106,632 shares during the last quarter. Finally, Bank of America Corp DE lifted its stake in Regeneron Pharmaceuticals by 2.8% during the first quarter. Bank of America Corp DE now owns 1,189,584 shares of the biopharmaceutical company’s stock worth $919,120,000 after purchasing an additional 32,158 shares during the last quarter. Institutional investors own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc is a biotechnology company that discovers, develops and commercializes medicines for serious medical conditions. The company uses human genetics, antibody technology and other biological research platforms to develop treatments in areas including eye diseases, cancer, cardiovascular and metabolic disorders, inflammatory diseases, infectious diseases and rare conditions.

Regeneron’s marketed products include EYLEA and EYLEA HD for certain retinal diseases; Dupixent, developed and commercialized with Sanofi, for multiple allergic and inflammatory conditions; Libtayo for certain cancers; Praluent for high cholesterol; Kevzara for rheumatoid arthritis and other inflammatory diseases; Evkeeza for homozygous familial hypercholesterolemia; and Veopoz for a rare immune-mediated disorder.